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Abstract We review the current state of knowledge of potentially useful drugs act-
ing on the recovery of consciousness in severely brain-damaged patients. Exploratory 
and retrospective studies as well as case reports on the sporadic cases of recovery 
are discussed regarding pharmacological treatments such as amantadine, levodopa, 
bromocriptine, apomorphine, methylphenidate, zolpidem, baclofen, and lamotrig-
ine. Potential underlying mechanisms explaining the effects of these drugs on the 
awakening and recovery of consciousness in this challenging population are also 
examined. Finally, we discuss the process of using single-subject methods to assess 
the off-label use of a specific medication.
 Introduction
Disorders of consciousness (DOC) resulting from a severe brain injury include coma 
[1], the unresponsive wakefulness syndrome (UWS, vegetative state) [2, 3] and the 
minimally conscious state (MCS) [4]. There are currently only a very few evidence-
based guidelines regarding the treatment of patients with DOC. Studies showed that 
some severely brain-damaged patients benefit from pharmacological treatments, 
brain stimulation techniques, rehabilitation, and/or sensory stimulation therapies; 
but, in general, responses to treatment still remain unsatisfactory [5–8]. By targeting 
various pathways of the central nervous system, several pharmacological agents can 
contribute to the recovery of consciousness in some patients. Sensory perception is 
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controlled by a complex neural network, which includes reticulothalamic cholinergic 
projections and thalamocortical and reticulocortical glutaminergic projections. 
Lesions in the white matter connections of these networks may affect consciousness 
and cognition [9], and several drugs including dopaminergic agents can act on this 
network and support recovery of consciousness.
Using psychoactive medications to enhance cognitive and behavioral perfor-
mance is challenging for several reasons. The mechanisms of psychoactive drugs 
are characterized by the types of receptors they activate or the neurotransmitters or 
ion transport processes they modulate. In contrast, the goals of treatment are to alter 
specific cognitive processes such as arousal, memory or behavioral phenomena 
such as aggression or initiation of functional activities. Unfortunately, there is no 
simple correspondence between these two levels of analysis. If a drug affects a sys-
tem that is relevant to our clinical goals, we can be sure it also affects other systems 
that we might not choose to manipulate. Thus, the decision to administer a psycho-
active drug typically requires one or more implicit or explicit hypotheses: “This 
drug binds to receptor class X. Activation of receptor class X is thought to enhance 
arousal. I hypothesize that increased arousal in this patient will enhance the reli-
ability of command following.” This is the motivation for trying the drug. But it may 
be that activation of receptor class X has a number of other effects that are negative 
and outweigh its value for enhancing arousal. Moreover, even if we successfully 
enhance arousal, it might be that the patient’s command following is primarily lim-
ited by apraxia rather than lack of arousal, and therefore command following may 
not result even if arousal is successfully enhanced.
Another challenge is the gap between the words we use to describe psychological 
and behavioral constructs and our growing knowledge of the complex and interactive 
nature of the brain. We have one word for “arousal,” but we know that arousal is affected 
by at least four different neurotransmitters, and we have come to understand that some 
have greater effects on “readiness to detect” and others on “readiness to act” [10, 11]. 
So saying that we want to enhance a patient’s arousal, itself, is too crude a statement.
Finally, psychoactive drugs ultimately act on some specific biological target, and 
to be beneficial, the patient must have that target available. A drug that stimulates the 
release of a natively produced neurotransmitter or which prolongs its presence in the 
synapse cannot be effective unless there is sufficient endogenous production of that 
neurotransmitter. A direct agonist of postsynaptic receptors cannot be effective 
unless there are sufficient downstream neurons to respond to that agonist. Thus, we 
hypothesize that there are particular patterns of neural network damage and preser-
vation that may predict whether a patient can respond to the drug, though at present 
we are far from being able to define these patterns and use them in treatment 
selection.
This chapter will summarize the current state of the art on potentially useful drugs, 
such as amantadine, levodopa, bromocriptine, apomorphine, methylphenidate, zolpi-
dem, baclofen, and lamotrigine, that can act on the recovery of consciousness in 
DOC patients. Recent neuroimaging studies on the effect of pharmacological treat-
ments will be discussed, and we will explore some potential underlying mechanisms 
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explaining the effects of these drugs on the recovery of consciousness. We will also 
comment on the process of using individual subject methods to investigate the 
off-label use of other medications that have not yet been adequately studied.
 Potential Pharmacological Treatments
 Amantadine
Amantadine is an old dopaminergic agent initially used in the treatment of 
Parkinson’s disease. It was also employed against influenza due to its antiviral prop-
erties, but due to the frequent mutations of the virus and to the advent of new drugs, 
it is no longer recommended as an antiviral drug. Amantadine increases the avail-
ability of dopamine in the striatum both at the pre- and postsynaptic levels. It facili-
tates the release of dopamine and delays its reuptake, resulting in an increase of 
synaptic dopamine concentration [9]. At the postsynaptic level, amantadine 
increases the number of dopaminergic receptors [12]. It is also a dose-dependent 
antagonist of the N-methyl-d-aspartate receptors.
The use of amantadine is correlated with a better outcome among severe trau-
matic brain-injured patients [13–15]. A retrospective study has shown that in 74 
acute traumatic patients diagnosed in UWS, the group treated with amantadine 
obtained higher scores on the Glasgow Coma Scale (GCS) [16] than the group who 
did not receive the drug when discharged from the intensive care unit [13]. Mortality 
was also lower in the treatment group than in the non-treatment group. Another 
study on 35 patients showed a higher functional improvement, as assessed with the 
Mini-Mental State Examination [MMSE] [17], the Glasgow Outcome Scale [18], 
and the Disability Rating Scale [DRS] [19], during a treatment of over 6 weeks in 
the acute phase of severe traumatic brain injury [20]. Similarly, Whyte et al. showed 
that patients with traumatic etiology receiving amantadine had better DRS scores 4 
months post injury than those who did not receive the treatment [14]. Note that these 
studies took place when patients were still in the acute or subacute stage and, thus, 
they do not provide information on patients with a slower recovery process or with 
chronic DOC and could potentially be biased by early spontaneous recovery.
Zafonte et al. reported a dose-dependent response to amantadine in one MCS 
patient examined 5 months after a brain trauma. During the treatment, the patient 
recovered his communication abilities, and the score on the Coma/Near-Coma 
(CNC) scale [21] increased. This effect was reversible when the treatment was 
stopped; and during its reintroduction, the patient could communicate again [22]. 
Another recent case report of a non-traumatic MCS patient also showed a dose- 
dependent response to amantadine, but when the dosage was increased to 200 mg 
per day, the patient presented unexplained tachycardia [23].
A well-designed controlled multicenter study has recently been conducted by 




amantadine in promoting recovery of consciousness in patients with DOC [24]. 
This double-blind, randomized, placebo-controlled trial of a 6-week duration study 
assessed 184 patients who were either in UWS or MCS 1–4 months after traumatic 
brain injuries. Patients were randomly assigned to receive amantadine or placebo 
treatment for 1 month and were followed for 2 weeks after the treatment was dis-
continued. In keeping with evidence from the rate of change during inpatient reha-
bilitation (i.e., due to spontaneous recovery or stimulation programs), both groups 
had improved during the 1-month period. Nonetheless, functional recovery (e.g., 
recovery of consistent response to commands, intelligible verbalization, reliable 
yes-no communication, functional use of objects) was faster in the amantadine 
group than in the placebo group, as measured by the improved DRS scores. Although 
improvements were generally maintained in the amantadine group after the washout 
period, the rate of functional recovery attenuated after stopping the treatment, and 
DRS scores were converging between the amantadine and placebo groups at the 
6-week follow-up assessment (Fig.  11.1). These results suggest that amantadine 
accelerated the pace of functional recovery during active treatment in patients with 
DOC when assessed in the acute and subacute settings. Note that exposure to aman-
tadine did not increase the risk of adverse events (e.g., seizures).
Most of the aforementioned studies only involved patients with traumatic brain 




















Fig. 11.1 Behavioral results of amantadine treatment as compared to placebo during a 6-week 
assessment period. DRS scores range from 0 to 29 with higher scores indicating more severe func-
tional disability. DRS scores improved faster in the amantadine group than in the placebo group 
during the 4-week treatment period. During the washout period (the last 2 weeks), the rate of 
recovery was slower in the amantadine group, and mean DRS scores were similar for the two 
groups at the 6-week mark. The bars denote the standard error (Taken from [24])
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of amantadine and methylphenidate in patients resuscitated after a cardiac arrest 
[25]. Out of a cohort of 588 acute patients, 16 patients received amantadine, 
 methylphenidate, or a combination of both. Compared to the control group, patients 
receiving neurostimulants trended toward an increased frequency of goal-directed 
behaviors at the bedside (i.e., command following) with an improved distribution of 
the Cerebral Performance Category scale and modified Rankin scale scores. These 
patients also showed a higher survival rate after hospital discharge. Even if this 
study suggests a potential therapeutic option for post-cardiac arrest patients in acute 
setting, it does not account for the spontaneous recovery bias. A controlled prospec-
tive trial is still needed to fully determine the effect of amantadine in pathologies 
other than brain trauma.
Finally, to date, only three studies used electrophysiology or neuroimaging tech-
niques to gather objective information about the amantadine efficacy in DOC 
patients. A first study used electroencephalogram (EEG) to show an increase of 
alpha activity and a decrease of theta activity in one UWS patient who clinically 
responded to amantadine [26]. A second case report of a non-traumatic MCS patient 
showed that during amantadine treatment when the patient was able to communi-
cate and use objects (i.e., emergence of MCS), the EEG data also showed an 
increase in predominant background alpha activity (10–11 Hz), while during base-
line and washout periods, the EEG showed moderately abnormal EEG background 
(7–8 Hz) [27]. Note that this case also presented a dose-dependent effect, but epi-
leptic facial myoclonus was observed during treatment, which led to the discontinu-
ation of amantadine. The third study conducted by Schnakers et  al. used 
fluorodeoxyglucose positron emission tomography in an ABAB paradigm in a post-
anoxic chronic MCS state who responded to amantadine [28]. Behaviorally, the 
patient improved at the motor level and responded to verbal commands after aman-
tadine treatment. The scores at the Coma Recovery Scale-Revised (CRS-R [29]) 
also increased substantially. Metabolically, amantadine-related increases in brain 
activity were measured in the fronto-temporoparietal network and in sensorimotor 
areas. These brain regions were previously hypometabolic when compared to 
healthy subjects’ scans, and their metabolism increased after 5 weeks of treatment, 
decreased after withdrawal, and resumed near-normal values after amantadine rein-
troduction (Fig. 11.2).
In conclusion, amantadine seems to be a suitable medication to promote recov-
ery of consciousness in patients with traumatic DOC, as well as other cognitive 
functions related to arousal and memory [30], but its effects in non-traumatic 
DOC are less clear. It can be started days to months post-injury and still produce 
benefits. Amantadine has a quick onset of action with functional results observed 
within the first 4 weeks of administration. The administered dosage varies between 
100 and 400 mg daily in adults (average of 200 mg a day). A few side effects have 
been reported so far, mostly in case report studies, ranging from mild to severe. 
More neurophysiological and neuroimaging studies are also needed to better 


























































































Fig. 11.2 Behavioral and metabolic effect of amantadine in one anoxic MCS patient. Upper panel: 
ABAB design showing treatment-related metabolic changes compared with healthy controls (C) in 
widespread bilateral fronto-temporo-parietal associative and right-sided sensorimotor areas. Lower 
panel: behavioral changes as assessed by the CRS-R total score during 21 weeks (black diamonds). 
Actimetry monitoring is represented as mean motor activity counted per week (red bars) or per 
month (white bars). Asterisks represent the significant difference of motor activity between condi-
tions (B1 > A2 < B2). RDLPFC, right dorsolateral prefrontal cortex (Taken from [28])




As amantadine, levodopa is a dopaminergic agent initially indicated in the treatment 
of Parkinson’s disease. Remarkable recovery was observed in the 1990s in a 24-year-
old man diagnosed with traumatic UWS for 6 months, who was able to speak a few 
days after the administration of levodopa [31]. Note that standardized validated diag-
nostic behavioral assessment was not used in this case and it was published before the 
introduction of the criteria of the MCS in 2002, and thus the initial diagnosis of UWS 
might have been inaccurate. Five other DOC patients with traumatic lesions also 
became more responsive after taking levodopa, which was initially given to treat 
extrapyramidal signs [32, 33]. In another uncontrolled unblinded study, eight UWS 
patients recovered signs of consciousness after the administration of progressive 
amounts of levodopa. All patients responded to commands within the first 2 weeks of 
treatment, and seven of them (including two assessed more than 9 months post-injury) 
were able to interact in a functional way [34]. Finally, in a last prospective case series, 
some remarkable responses to l-dopa/carbidopa were observed in 9 out of 11 trau-
matic and non-traumatic UWS patients. The effects were observed within 10 days of 
treatment (275 mg/day) and included the recovery of command following and recip-
rocal interaction. The authors suggested that the behavioral improvement was due to 
the treatment itself and not to the spontaneous recovery because the time since injury 
was between 30 and 180 days, and patients were in a UWS for at least 1 month with-
out any improvement before being included in the trial [35]. Nevertheless, none of 
these studies formally controlled for natural recovery.
 Bromocriptine
Bromocriptine is another dopamine agonist used primarily to treat Parkinson’s dis-
ease. This agent, less studied, is mainly an agonist of the postsynaptic dopamine D2 
receptors. It has been associated with a higher rate of patients recovering from a 
posttraumatic UWS in a retrospective study [36]. However, in a 6-week double- 
blind, placebo-controlled, crossover study, bromocriptine (5 mg twice daily) did not 
improve attentional skills in 12 conscious patients with moderate-to-severe trau-
matic brain injury [37]. Moreover, it possibly induced negative side effects (e.g., 
dizziness) in some patients.
 Apomorphine
Apomorphine is a nonselective dopaminergic agonist, which activates D1 and D2 
receptors with a preference for the latter [38]. This therapy was initially indicated to 
treat Parkinson’s disease and erectile dysfunction but it has also shown positive 




apomorphine 104 days after a brain trauma suddenly recovered consciousness after 
1 day of treatment. He was able to move his legs upon request and to answer yes-no 
questions, which was not the case before [39]. After stopping the treatment, the 
patient remained fully conscious, and a considerable functional recovery was still 
maintained. Diffusion tensor imaging showed a reduction in thalamocortical and 
corticothalamic projections, as expected in such patients [40]. Another uncontrolled 
case study of eight UWS and MCS patients with traumatic etiology who were 
treated continuously with apomorphine showed a recovery of consciousness for all 
patients except one, with an improvement in CNC and DRS scores [41]. These 
improvements lasted for at least 1 year, even after stopping the treatment. As above, 
the design used in these two studies does not distinguish between improvements 
induced by apomorphine and ones that could have occurred spontaneously.
More studies in DOC patients are needed to confirm the potential benefit of apo-
morphine (but also levodopa and bromocriptine) using double-blind placebo- 
controlled designs and, if possible, complement these with neuroimaging 
techniques.
 Methylphenidate
This neurostimulant was initially used for children presenting attention-deficit 
hyperactivity disorders, and it was also prescribed for narcoleptic patients. This 
agent increases the release of dopamine and noradrenalin while blocking their reup-
take and inhibiting monoamine oxidase, which increases noradrenergic activity in 
the striatum and other brain areas such as the caudate nucleus and the medial frontal 
cortex [9].
Only a few studies using methylphenidate have been conducted in DOC patients 
to improve the level of consciousness. One study suggested that the early use of 
methylphenidate in intensive care is associated with shorter hospital stays after 
severe trauma [42]. In a retrospective study, comatose post-cardiac arrest patients 
receiving neurostimulants trended toward improved rate of following commands, 
survival to hospital discharge, and increases at several behavioral scales [25]. 
Another study including 14 patients with impaired consciousness after acquired 
brain injury reported improvement in GCS scores after methylphenidate administra-
tion. This behavioral amelioration was mainly associated with increased cerebral 
glucose metabolism in the posteromedial parietal cortex, suggesting that this brain 
area, which is part of the neural network for consciousness, may be the relevant 
structure for the pharmacological response to methylphenidate treatment in DOC 
patients [43]. On the other hand, a meta-analysis of command following and com-
munication activity in 22 chronic patients with DOC (17 of traumatic etiology) did 
not show any clinical improvement on the percentage of responses to command 
after the administration of methylphenidate [44].
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Methylphenidate has mostly been studied for its positive effect on attention and 
memory in the acute and subacute phases of recovery in patients suffering from 
moderate to severe brain injury [45–49]. More recently, methylphenidate has been 
associated with a global reduction of cerebral blood flow and a decreased activity in 
the left posterior superior parietal cortex and parieto-occipital junction during task 
performance. This finding suggests a compensatory mechanism by which the drug 
ameliorates attention impairments in traumatic brain-injured patients [49].
Finally, ten children and teenagers in a UWS and MCS were treated with a com-
bination of dopaminergic drugs (amantadine, methylphenidate, bromocriptine, 
levodopa, pramipexole) and improved their responses to structured stimuli in an 
uncontrolled, unblinded prospective study [50].
 Zolpidem
Zolpidem is an imidazopyridine which acts like an agonist on subtype 1 of the 
inhibiting receptors of the gamma-aminobutyric acid (GABAA). This agent was ini-
tially recommended in the treatment of insomnia and presents sedative, anticonvul-
sive, anxiolytic, and myorelaxant effects.
Many studies have now reported the use of zolpidem as an “awakening” agent 
among UWS and MCS patients. This drug produces, occasionally, a clear paradoxi-
cal temporary effect on the level of consciousness in patients with severe brain dam-
age. The effect of zolpidem was described for the first time in 2000 after the 
fortuitous discovery in an allegedly UWS patient who had had a traumatic brain 
injury 3 years earlier and who started to communicate 20 min after the administra-
tion of the medication [51]. Clauss and colleagues subsequently reported impressive 
effects of this drug in four other UWS patients who had suffered a traumatic or 
anoxic cerebral lesion 3–5 years before [52]. Patients were able to answer questions, 
speak, and feed themselves shortly after taking a single dose of zolpidem (10 mg). 
Improvements were also observed at the GCS scale and the Rancho Los Amigos 
scale [53]. The level of consciousness of these patients returned to its initial state 4 h 
after the administration of the drug, but an improvement was observed again at the 
time of readministration. Similar transitory effects have also been reported among 
patients in MCS resulting from cerebral anoxia or encephalitis [54–57]. Some case 
studies underlined, however, the absence of improvement among other patients suf-
fering from post-anoxic encephalopathy or severe brain trauma [58–60].
The percentage of responders has recently been investigated among patients in 
UWS and MCS. The first preliminary study showed that among 15 patients, only 
one indicated a significant clinical response transitioning from UWS to MCS. The 
remaining 14 patients did not show any improvement [60]. In a subsequent placebo- 
controlled double-blind crossover study, among 84 DOC patients of at least 4-month 
duration, only four showed significant recovery such as increased movement, social 
interaction, command following, and functional object use [61]. The effect typically 




restless movements). Thus, in these two studies, around 5% of the participants 
responded to zolpidem, and the responders could not be distinguished in advance 
from the nonresponders.
An EEG study in a single post-stroke chronic UWS patient showed that zolpi-
dem could produce less dramatic changes than the ones previously reported [62]. 
For instance, after zolpidem, the patient could open her eyes sustainably and start 
yawning, which was correlated with activation of EEG cortical activity [63]. Thus, 
although zolpidem may produce rapid and dramatic improvements in a few cases, 
its effects are subtle or absent in most patients. Along the same lines, a clinical trial 
in 60 chronic patients with DOC showed that only one MCS patient showed behav-
ioral improvements (i.e., functional use of objects) [64]. However, following this 
performance, the patient was then reassessed in a double-blind placebo-controlled 
trial but failed to show any clinical improvement. Four other patients showed 
increased total scores at the CRS-R after zolpidem intake that were never observed 
before, suggesting that the drug can induce inconsistent effects.
To assess the efficacy of zolpidem treatment according to the patients’ site of 
injury, 127 subacute patients in UWS were evaluated over a 1-week daily treatment. 
Patients were divided into two non-brainstem injury (i.e., brain countercoup contu-
sion and brain compression injury) and two brainstem injury groups (i.e., primary 
and secondary brainstem injuries). Under zolpidem, the level of consciousness of 
the non-brainstem injury groups was better than before treatment, whereas no 
changes were observed for the brainstem injury groups. SPECT measures also 
showed increased perfusion in brain-damaged areas in the non-brainstem injury 
groups, while no changes could be observed in the brainstem groups. These findings 
suggest positive effects of zolpidem on brain functions only in the absence of brain-
stem injuries [65].
Several studies were interested in the mechanisms that could explain the effect of 
zolpidem. Single-photon emission computed tomography studies showed that zolpi-
dem increases the cerebral metabolism of hypoactive areas following traumatic or 
anoxic lesions [51, 52, 66]. In the same line, using PET scan in one MCS patient, 
improvement of neuropsychological performances was correlated with an increase 
in cerebral metabolism in the frontal and postrolandic areas after zolpidem intake. 
Activations were also observed in anterior cingulate and orbitofrontal cortex, areas 
known to be involved in motivational processes [54]. Using resting state fMRI in a 
single post-stroke chronic UWS patient who showed minimal improvement after 
zolpidem (see above, [62]), increased BOLD signal was transiently measured in a 
widely distributed cortico-subcortical network (i.e., frontal cortices, anterior cingu-
lated areas, thalamus and caudate nucleus). In comparison, a healthy participant 
showed a deactivation of the frontal, parietal, and temporal cortices after zolpidem 
administration. Those BOLD signal changes in the UWS patient also correlated with 
concentrations of extravascular metabolites in the frontal cortex. These findings sug-
gest a zolpidem-induced modulation of neurometabolism with an increased metabo-
lism related to a dormancy switch-off in a widespread frontoparietal network [67]. 
Consistently, another PET study showed metabolic level increases after zolpidem 
intake in a set of hypoactive areas encompassing the limbic loops (i.e., orbitofrontal 
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cortex) in three chronic post anoxic MCS patients [68] (Fig.  11.3a). All patients 
recovered functional communication after administration of zolpidem, and none of 
them presented structural lesions on the brain areas showing increased metabolism 
after zolpidem. Additionally, zolpidem responders also seemed to present an increase 
in EEG power at ∼15–30 Hz associated with an attenuation of ∼6–10 Hz power 
after the zolpidem intake [69] (Fig.  11.3b). Another recent chronic post-anoxic 
UWS case report showed an increase of amplitude and voltage with a theta-beta 
rhythm over temporal areas along with an increase of CRS-R score during higher 
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Fig. 11.3 Neuroimaging and neurophysiology of zolpidem responders. (a) Brain metabolism 
assessed with PET scan. Blue areas show decreased brain metabolism after placebo and after zol-
pidem intake, and red brain areas show recovery after zolpidem in three MCS patients. (b) Brain 
electrical activity assessed with EEG. Power spectra measured from midline EEG channel Fz-Cz 
recordings from three MCS patients. The average spectral power in the hour prior zolpidem dose 
is shown in red and in blue the average spectral power in the 20–60 min after the zolpidem dose 




A mechanism of cell dormancy was proposed to explain the effect of zolpidem: 
certain nonspecific areas of the brain, adjacent or distant to the initially damaged 
zones (e.g., the ipsilateral and contralateral hemisphere or the cerebellum), might be 
inhibited by the lesion. These inactive parts of the brain would recover their func-
tion after taking zolpidem, generating a recovery of consciousness [51, 54, 66, 71]. 
In line with this hypothesis, a study using magnetoencephalography showed that 
zolpidem decreased the number of pathological slow waves associated to dormant 
cerebral tissue in a patient who had a stroke [72].
From a molecular point of view, changes could take place at the level of 
glutamate and GABA neurotransmitters close to the cerebral lesions. The release of 
glutamate produces an excitotoxicity and an excess of inhibitory GABA neurotrans-
mitters as well as a long-term oversensitiveness of the GABAA receptors [51, 52]. 
The inhibitory neurotransmitters, while binding to the receptors of the ionic chan-
nels, generate a reduction of metabolism and blood flow in the adjacent cerebral 
areas, thus causing a state of cell dormancy. While binding to GABAA receptors of 
dormant cells, zolpidem provokes the inversion of the abnormal state of the neurons 
and associated metabolic inhibition. The “GABA impairment hypothesis” was thus 
proposed to explain the effect of zolpidem on recovery of consciousness, which 
states that zolpidem may act on the recovery of consciousness by reversing the 
impairment of GABA and, hence, by restoring normal ratio between synaptic exci-
tation and inhibition [73]. According to the mesocircuit model (see below), zolpi-
dem could interact with the limbic loops of the brain and modulate subcortical 
connections, more particularly the globus pallidus, which would bring the thalamo-
cortical activity back to normal and would allow a recovery of consciousness [74].
In conclusion, zolpidem responders are rare, i.e., around 5% of UWS and MCS 
patients from both traumatic and non-traumatic etiology. The dosage varies among 
studies, but the standard dose is 10 mg with an effect that lasts a few hours. Several 
hypotheses have been proposed regarding the underlying mechanism of zolpidem 
paradoxical responses, but future research is still needed to better understand the 
mechanism of zolpidem in enhancing consciousness and to identify biomarkers that 
can predict a clinically meaningful treatment response.
 Baclofen
Baclofen is an agonist agent of the GABAB receptors, which acts on the posterior 
horn of the spinal cord and which is used mainly against spasticity. This symptom 
is frequently observed after central nervous system lesions and can limit voluntary 
movements in patients with DOC. The antispasmodic effect of baclofen remains 
modest when it is administered orally. A direct and continuous perfusion of baclofen 
in low doses in the cerebrospinal fluid is more effective. Intrathecal baclofen ther-
apy can be a useful treatment against severe spasticity among DOC patients, which 
improves the quality of life by reducing pain-related spasms and contracture 
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formation [75]. It can also help control persistent autonomic dysfunctions such as 
tachycardia, tachypnea, fever, and breathing difficulties [76].
In uncontrolled case studies, some impressive cases of recovery were reported in 
UWS patients who were treated with baclofen in the subacute setting [77–79]. A 
positive effect of baclofen was also observed in five UWS patients treated for spas-
ticity in the chronic stage (at least 19 months post-injury). Two weeks after the start 
of the treatment, all except one patient presented clinical improvement, which 
remained stable until the end of the 6-month follow-up interval [80]. Improvements 
went from an increase in vigilance to a recovery of consciousness, as revealed by 
changes in CRS-R scores. Similarly, two traumatic MCS patients with spasticity 
received intrathecal baclofen and emerged from the MCS, but their cognitive defi-
cits remained severe [81]. In another recent prospective study, two out of eight DOC 
patients that had spasticity showed a marked and sustained improvement after intra-
thecal baclofen therapy, and they emerged from MCS [82]. Long-term outcome 
(10-year follow-up) has also been studied in a cohort of 53 severe traumatic or 
hypoxic patients treated with intrathecal baclofen. A good functional recovery 
occurred in the traumatic group but not in the hypoxic group, which suggests that 
hypoxic patients tend to be less responsive to the baclofen treatment than traumatic 
patients [83]. Among the traumatic group, 21% patients died, 30% patients were 
severely disabled or in a UWS, and 49% had good recovery of consciousness. 
Patients who had a good recovery tended to receive baclofen later, and they needed 
lower doses of baclofen, while poor long-term outcome was associated with early 
development of severe symptoms of dysautonomia associated with hypertonia [84].
Several assumptions have been made to explain the effects of baclofen on recov-
ery of consciousness. Some authors suggest a modulation of motor impulses of the 
spinal cord on possible cortical reactivation [80]. By improving nervous conduction 
in the demyelinated axons, Baclofen could possibly accelerate the repair of diffuse 
axonal injury [85]. It has also been hypothesized that intrathecal baclofen therapy 
may act by reducing the overload of dysfunctional sensory stimuli reaching the 
injured brain [75]. A modulation of the sleep-wake cycle has also been considered 
as a mechanism responsible for the effect of baclofen [80]. However, as in many of 
the medications discussed above, studies of baclofen which adequately control for 
natural recovery are lacking.
 Lamotrigine
Lamotrigine is an agent used in the treatment of epilepsy and bipolar disorders. By 
inhibiting the voltage-dependent sodium channels, it stabilizes the neuronal mem-
brane and inhibits glutamate release. Its effects on the sodium ion channels contrib-
ute to the antiepileptic effects, while the antiglutamatergic agents act more on the 
psychotropic effects with a possible neuroprotective action [86, 87]. Functional 
improvement of patients with severe brain injuries has been observed in only one 




and cognition combined with an earlier discharge from hospital [88]. This uncon-
trolled unblinded study suggested a possible effect on functional recovery, particu-
larly in patients who had spontaneously emerged from the MCS. This medication 
might influence other aspects of cognitive performance than the level of conscious-
ness per se [89].
 Mechanisms Aiming to Explain the Possible Positive Effects 
of Pharmacological Treatments
Each drug affects one or more neuronal pathways. Amantadine, levodopa, bro-
mocriptine, methylphenidate, and apomorphine act mainly on the dopaminergic 
system, whereas zolpidem and baclofen affect preferentially the GABAergic system 
(albeit at different locations in the nervous system). The subjacent neurological 
mechanisms to the positive effects of these drugs are currently not well understood. 
As we have seen, amantadine and zolpidem would increase the metabolism of hypo-
active cerebral regions [28, 90]. Zolpidem would play a main role in the GABAergic 
system of the limbic loops in the brain [90], whereas baclofen would act more on 
the spinal cord and might support the regeneration of motor neurons [80].
More specifically, the favorable effect of dopaminergic agents on arousal and 
awareness in patients with DOC may reflect enhanced neurotransmission in the dopa-
mine-dependent nigrostriatal, mesolimbic, mesocortical, and/or thalamic pathways 
(Fig. 11.4) [91, 92]. These pathways mainly originate in the brainstem and project 
forward to interact with different structures of the midbrain and cerebral cortex. The 
nigrostriatal pathway, which starts in the substantia nigra and ends in the basal gan-
glia or striatum, plays a major role in behavior initiation and motor functions. The 
mesolimbic pathway, which projects from the midbrain ventral tegmental area to the 
nucleus accumbens in the ventral striatum, is associated with emotional processes, 
motivation, learning, and memory. The mesocortical circuit, encompassing excitatory 
projections from the ventral tegmental area to the prefrontal cortex, is believed to be 
involved in cognition and executive function (via the dorsolateral prefrontal cortex) as 
well as in emotions and affect (via the ventromedial parts of the prefrontal cortex) 
[91, 92]. In addition to these three pathways, another system including the thalamus 
is important for mediating arousal and awareness and hence might play a key role in 
the functional recovery of severe brain-injured patients. In this thalamic pathway (see 
the mesocircuit model below), dopamine exerts effects on the thalamus and the basal 
ganglia, which then connects to the supplementary and primary motor areas, the dor-
solateral prefrontal cortex, and the limbic structures [93].
Dopaminergic agents have thus been suggested to increase thalamic tonus firing 
via the striato-thalamic projections [94]. The mesocircuit model has been proposed 
to explain the various pharmacological effects on the recovery of consciousness 
[95] (Fig. 11.5). The central thalamic nuclei (CTN) seem particularly important in 



















Fig. 11.4 Schematic illustration of the potential mechanisms of action of pharmacological agents 
on the level of consciousness. According to the mesocircuit model [74], dopamine facilitation of 
the striatum’s output or the direct modulation of the frontal cortex would explain the restoration of 
anterior forebrain activity within the loop connections of the frontal cortex, striatum, pallidum, and 
thalamus. Zolpidem would act more on the globus pallidus by directly inhibiting it (Taken from 
[92])














Fig. 11.5 The mesocircuit model that aims to explain the mechanisms of pharmacologically 




the emergence of consciousness. They receive ascending projections coming from 
the brainstem encompassing the arousal systems that control the activity of many 
cortical and thalamic neurons during the sleep-wake cycle. The CTN are strongly 
nerved by cholinergic, serotoninergic, noradrenergic afferents of the arousal system 
in the brainstem. These same neurons of the CTN are also innervated by the down-
ward projections coming from the areas of the frontoparietal cortex. Collectively, 
these ascending and descending pathways seem to modulate the level of conscious-
ness [95]. The frontoparietal cortex (and its subcortical modulation via striatum, 
globus pallidus, and thalamus) is also prevalent for the emergence of consciousness. 
Thalamocortical projections coming from the CTN activate in normal conditions 
the neurons of the cortex and striatum. Lesions at this level result in a reduction of 
cerebral metabolism. Neurons of the striatum inhibit the internal globus pallidus but 
require a strong basic synaptic activity and elevated levels of dopaminergic innerva-
tions in order to maintain their state in activity. Without projections of the striatum 
to the globus pallidus (e.g., by a lack of dopaminergic innervations), the globus pal-
lidus itself will inhibit the CTN, which in turn will inhibit the cortical structures, 
and this sequence could, thus, generate consciousness disorders. Disturbances in 
this mesocircuit influence the total dynamics of the dominating corticothalamic and 
frontoparietal systems [74]. Dopaminergic drugs could, therefore, facilitate projec-
tions of the striatum on the globus pallidus, which would modulate the frontopari-
etal cortical neurons and would restore the cortico-subcortical loops. Zolpidem is 
thought to act directly on the globus pallidus and would make it possible to inhibit 
it (as it is usually the case due to the action of the striatum), which would also 
restore the activity of the CTN, whereas the glutamatergic agents (e.g., lamotrigine) 
would intervene directly on the CTN (Fig. 11.5).
 Single-Subject Methods to Assess the Off-Label Use of Specific 
Medication
As noted, there are very few drugs for which we have strong evidence of clinical 
efficacy in treating specific cognitive or behavioral problems after severe 
TBI. Important questions remain even for the most rigorously studied drugs about 
the most likely responders and the optimal treatment timing, dosage, and duration. 
For most of the drugs in this review, we have even less evidence: evidence from 
other populations coupled with anecdotal evidence or evidence from small or meth-
odologically flawed studies. Nevertheless, many of these drugs are in prevalent use 
in an “off-label” fashion in the hope that they will be effective [96]. If the evidence 
does not allow us to predict a positive response with confidence before we initiate 
treatment, then surely we have a responsibility to know after treatment whether the 
drug resulted in clinical improvement and whether it produced important adverse 
effects. Thus, a practitioner using psychoactive drugs off-label should have a plan in 
place for determining the drug’s effects in retrospect and for determining when to 
consider tapering the drug in the future.
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Single-subject experimental designs, also referred to as “N-of-1 studies,” pro-
vide useful options for evaluating a drug’s effect in the individual patient [97, 98]. 
In this approach, the tools of research are used to answer important clinical ques-
tions in the individual. The generalizability of this answer is not of concern as long 
as we know the effects in the patient we are treating. In the facility of one of the 
authors (JW), this process, within certain well-defined constraints, is not defined as 
research, does not require individual IRB review, and does not require informed 
consent to participate in research (though we are always careful to discuss the fact 
that the treatment itself is off-label). Single-subject designs may include randomiza-
tion, specific schedules of drug administration, use of specific measurement tools, 
and sometimes blinded or placebo-controlled administration.
There are three basic designs that are most applicable to the evaluation of drug 
effects: A-B designs, A-B-A designs, and repeated crossover designs, in increasing 
order or rigor [99]. For all of these designs, the first task is to select the outcome 
measures that will be used to assess the drug’s effects. Whenever possible, we select 
a measure of a very proximal outcome of the drug that may or may not be clinically 
meaningful, but that will help us ensure that the drug, at the dose given, is physio-
logically active. For example, in the hypothetical scenario where we hope to increase 
arousal to achieve more reliable command following, we might choose a measure of 
amount of time spent with the eyes open as a measure of the arousal response, 
though it is not our ultimate clinical goal. We also need, of course, a measure of the 
clinical goal; in this case, we might choose percent of a standard set of commands 
that are followed in each session. Finally, when we know that certain adverse effects 
of the drug are particularly likely, we might have in place a measure of those effects 
to alert us to their increase.
In planning the drug assessment, we must decide between standardized and psy-
chometrically evaluated measures and measures tailored to the individual patient’s 
problem. We rely on standardized measures where they are clearly applicable to the 
patient’s problem, but often our treatment goals are too specific to match any exist-
ing measure, and then we must create one for the individual. This is typically a 
team-centered process and may be prompted by such questions as, “How would you 
know if this drug is having the desired effects? What would you actually observe 
if the drug does increase ___? How would you measure that change?”
In the A-B design, one begins collecting data with the chosen outcome measures 
for a period of time (the A phase) before the drug is started, conducting repeated 
measurements. Then one continues with those same repeated measurements after 
introducing the drug (the B phase), looking for a change in the measures that cor-
responds to the transition from A to B. In some cases visual inspection may reveal a 
clear change in the level of performance. Statistical evaluation is more controver-
sial. In many cases the multiple performance data points are not statistically inde-
pendent, violating the assumptions of many traditional statistical tests. One crude 
statistical approach involves a “celeration line” [100]. In this technique, a regression 
line is plotted through the A-phase data and continued forward into the B phase. The 
actual B-phase data points that lie above and below the celeration line are counted 




approximately 50% of B-phase data will likely be above and 50% below the line. 
Sharp deviation from this 50/50 ratio suggests a drug effect. However, it has been 
pointed out that, unless there is a very large volume of A-phase data and/or the vari-
ability in the A-phase is low, the confidence interval around the celeration line is 
likely to be wide. This means that having far more than 50% of B-phase data above 
or below all possible celeration lines could occur easily by chance (Fig. 11.6).
The A-B-A design is identical except that, after an interval of treatment, the drug 
is withdrawn again and one looks for a drop in performance that corresponds to the 
transition from B back to A (after which, of course, the drug can be reintroduced, if 
appropriate). In the repeated crossover design, one transitions back and forth 
between providing the drug and withholding the drug, ideally at random intervals, 
collecting the same outcome data throughout. In this design, the repeated crossovers 
reduce the likelihood that some other intervening events (an illness, another treat-
ment, etc.) might actually be responsible for the change, since no other event is 
likely to follow the same randomly reversing schedule.
The A-B design is the most feasible to implement in the clinical setting, since it 
corresponds to routine clinical practice aside from the fact that measurement begins 
prior to treatment. Unfortunately, this design rarely provides a clear conclusion, as 
noted above. In addition to performance variability, if there is already a non-zero 
slope, one is challenged to determine that the slope is changed by the treatment. Just 
as in formal research, more variability requires a larger amount of data to reach 
conclusions, and this is often not feasible to collect in a time-limited clinical pro-
gram. In addition, if the drug being administered requires gradual dose increases, 
this further undermines the ability to link behavioral changes to the drug.
The A-B-A design overcomes some, but not all, of these problems. Variability in 
the measured performance still presents a challenge, as does gradual introduction and 
withdrawal of the drug. However, the confounding between an ongoing recovery 
slope and the anticipated drug effect is addressed, because in the reversal from B back 
to A, recovery should still lead to improvement, whereas the drug withdrawal should 
lead to deterioration (Fig. 11.6). If the data clearly support the notion that the drug 
was associated with the improvement and deterioration, one can be reasonably confi-
dent of that conclusion. However, if improvement and deterioration linked to the drug 
are not evident, this could be due to excess variability, to the fact that ongoing recov-
ery outweighs drug withdrawal effects, or to the fact that recovery has proceeded to 
the point that the drug is no longer needed. Although this is a scientific limitation of 
the A-B-A design, it is less of a limitation clinically. The main clinical question once 
a patient is receiving a drug is whether they should stop it or continue it.
The strongest design in terms of the ability to link any performance changes to the 
drug is the multiple crossover design. If a sufficient number of crossovers are per-
formed at random intervals, then drug condition is unlikely to be confounded with time 
(recovery) or other medical or social events (Fig. 11.6). The main limitation of this 
design relates to the pharmacokinetics of the drug of interest. This design is well suited 
to drugs with rapid onsets of action which do not need to be introduced or withdrawn 
gradually, such as the psychostimulants [44]. Such drugs can be randomized at inter-
vals of one to a few days, with little carryover of the drug’s behavioral effects. For drugs 
with slower onsets of action (e.g., selective serotonin reuptake inhibitors) or those that 
require gradual drug titration (e.g., bromocriptine), such designs are rarely feasible.















































Weighing patient, drug, and measurement factors together suggests an optimal 
management approach [101]. In the early weeks and months post-injury, off-label 
prescribing of psychoactive drugs should be minimized. By definition, the effects of 
such drugs are not known with confidence and have a reasonable likelihood of 
impairing as well as facilitating recovery. Because of the natural slope and variabil-
ity of recovery seen in this phase, it is highly unlikely that the effect of the drug 
chosen can be determined with confidence. Drugs that have been shown in large 
group studies to benefit most patients treated can be used in the early period, even 
though their effects may not be demonstrable in the individual. As recovery slows 
and variability in performance diminishes, the mandate to intervene to augment 
natural recovery becomes more pressing, and the ability of the measurement meth-
ods to document a treatment response becomes greater.
In practice, it remains useful to define patient-specific goals and measure perfor-
mance with quantitative behavioral metrics before committing to pharmacologic 
intervention. The preliminary data may suggest that it will be impossible to evaluate 
a treatment response in the time available, that improvement over time is suffi-
ciently brisk that there is no urgency to intervene, or that the pattern suggests another 
treatment approach rather than medication. But where the preliminary data demon-
strates modest variability and lack of natural improvement, one can move forward 
with creative treatment evaluation methods.
 Conclusion
Amantadine is the only drug with strong evidence from randomized controlled trials 
to demonstrate an impact on recovery of consciousness in DOC [24]. Even for aman-
tadine, questions remain regarding its benefits for those with non-traumatic injuries, as 
well as the optimal dose, timing, and duration of treatment. Zolpidem has clearly been 
shown to lead to abrupt increases in the level of consciousness in a small minority of 
DOC patients, but, as yet, the factors that predict drug response are not fully known.
No strong evidence currently supports or disproves the use of other pharmacologi-
cal agents in order to improve the level of consciousness in DOC patients. As dis-
cussed, a number of small and uncontrolled case or cohort studies have reported a 
positive clinical response. Transitory or permanent improvements have been observed 
among some UWS or MCS patients of various etiologies. Reported effects were vari-
able, ranging from increase in wakefulness, partial recovery of consciousness, and 
motor, verbal, or communication functions to full recovery of cognitive functioning.
Some of the reviewed treatments (e.g., amantadine, zolpidem, baclofen) seem to 
benefit patients with severe DOC, whereas others (e.g., methylphenidate, lamotrig-
ine) seem to possibly be more beneficial for brain-damaged but conscious patients 
improving their attention-deficit disorder. Positive drug effects have been observed 
from a single dose (e.g., zolpidem) or from continuous treatment (e.g., amantadine, 
baclofen, levodopa).
These studies mainly come from case or cohort reports which cannot disentan-
gle the drug effect from natural recovery. Studies are also influenced by the extreme 
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heterogeneity of DOC, such as the site of neuropathological lesions, time elapsed 
between injury and the introduction of the treatment, confounding drugs received, 
and medical comorbidities. Moreover, it is difficult to compare between studies 
since they lack homogeneity in methodology and differ in the duration of treat-
ment, administered doses, and patients’ demographics and clinical status. 
Measurement tools and behavioral scales are also very different across studies, and 
a standardization of bedside assessment seems necessary. Additional placebo-con-
trolled, double- blind randomized multicenter studies are necessary before drawing 
conclusions about the role of other medications in these challenging patients.
Importantly, there is little reason to believe that any pharmacologic agent can 
benefit all patients with DOC, given the heterogeneity of pharmacologic mecha-
nisms and the variation in site and severity of neuropathology. Thus, research is 
needed to understand the pharmacologic targets relevant to restoration of conscious-
ness and to identify biomarkers that allow selection of patient subgroups with the 
ability to respond to specific pharmacologic probes. This will allow conduct of ran-
domized trials in patient groups “enriched” with the necessary brain substrates for 
therapeutic response. Efforts to advance pharmacologic treatments for DOC should 
focus on the conduct of large parallel group studies. Clinicians practicing in the face 
of minimal evidence should consider deferring off-label drug intervention to the 
point in recovery when positive or negative impacts of the drug can be recognized.
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